Sun Pharmaceutical has announced that the stockholders of Organon & Company have approved the proposals in connection with the previously announced merger transaction under which Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., an indirect wholly owned subsidiary of Sun Pharma.

The shareholder approval marks an important milestone toward completion of the proposed transaction.

The acquisition remains subject to the satisfaction of the remaining customary closing conditions, including applicable regulatory approvals.